Generic drug
Propafenone price, strengths & recalls
Pharmacies pay $3.52 for 30 tablets of Propafenone 150 mg tablet this week, and from $3.52 to $18.36 across its 6 priced strengths and forms. 11 manufacturers make it. 4 recalls are ongoing. Its official label last changed on March 31, 2025.
4 open recallsGeneric- Fair cash price
- $14.55
- Strengths
- 6
- Makers
- 11
- Updated
- Nov 11
Propafenone price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 225 mg (12 hr) extended-release capsule | $0.2624 | $7.87 / 30 capsules |
| 325 mg (12 hr) extended-release capsule | $0.6121 | $18.36 / 30 capsules |
| 425 mg (12 hr) extended-release capsule | $0.6045 | $18.14 / 30 capsules |
| 150 mg tablet | $0.1174 | $3.52 / 30 tablets |
| 225 mg tablet | $0.2092 | $6.27 / 30 tablets |
| 300 mg tablet | $0.3699 | $11.10 / 30 tablets |
The lowest cost per tablet is 150 mg tablet at $0.1174. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.
Supply status: shortages & recalls
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Propafenone
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use PROPAFENONE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for PROPAFENONE HYDROCHLORIDE TABLETS.PROPAFENONE HYDROCHLORIDE tablets, for oral useInitial U.S. Approval: 1989
WARNING: MORTALITY
In the National Heart, Lung, and Blood Institute's Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multicenter, randomized, double-blind trial in subjects with asymptomatic non-life-threatening ventricular arrhythmias who had a myocardial infarction more than 6 days but less than 2 years previously, an increased rate of death or reversed cardiac arrest rate (7.7%; 56/730) was seen in subjects treated with encainide or flecainide (Class IC antiarrhythmics) compared with that seen in subjects assigned to placebo (3.0%; 22/725). The average duration of treatment with encainide or flecainide in this trial was 10 months.
The applicability of the CAST results to other populations (e.g., those without recent myocardial infarction) or other antiarrhythmic drugs is uncertain, but at present, it is prudent to consider any IC antiarrhythmic to have a significant proarrhythmic risk in patients with structural heart disease. Given the lack of any evidence that these drugs improve survival, antiarrhythmic agents should generally be avoided in patients with non-life-threatening ventricular arrhythmias, even if the patients are experiencing unpleasant, but not life-threatening, symptoms or signs.
WARNING: MORTALITY
|
See full prescribing information for complete boxed warning.
• An increased rate of death or reversed cardiac arrest rate was seen in subjects treated with encainide or flecainide (Class IC antiarrhythmics) compared with that seen in subjects assigned to placebo. At present, it is prudent to consider any IC antiarrhythmic to have a significant risk of provoking proarrhythmic events in patients with structural heart disease.
• Given the lack of any evidence that these drugs improve survival, antiarrhythmic agents should generally be avoided in patients with non-life-threatening ventricular arrhythmias, even if the patients are experiencing unpleasant, but not life-threatening, symptoms or signs.
|
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Generic makers
- 8 approved generic applications on the market
Propafenone questions
How much does propafenone cost without insurance?
Pharmacies pay about $3.52 for 30 tablets of propafenone 150 mg tablet ($0.1174 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $14.55. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is propafenone in shortage?
No shortage is reported for propafenone right now. We check the national shortage list every day.
Has propafenone been recalled?
6 recalls on record, 4 ongoing. Recalls name specific lots - check yours.
When did the propafenone label last change?
The official label was last updated on March 31, 2025 (version 6). See what changed.
Talk about propafenone
No comments yet. Questions, tips, what worked for you - start the conversation.